The Pharma Data

JUNE 17, 2022

About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). 2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. Our ambition is to be the world’s leading and most valued generics company.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

APRIL 4, 2023

About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). 1 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. Our ambition is to be the world’s leading and most valued generics company.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It contains the antiviral medications nirmatrelvir and ritonavir. billion in pharmaceutical sales from 2021. billion in 2022, a 23.43

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 23, 2020

This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN), headquartered at Hyderabad, India , manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52